drugset / Trial / NCT02207946

Botulinum Toxin A to Treat Arm Tremor

NCT02207946 ↗

Phase 2 Completed 30 enrolled Merz Pharmaceuticals GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.

Timeline

Start
2014-12-05
Primary completion
2016-05-09
Completion
2016-09-26

Outcome

Missed primary endpoint

registry analysis (superiority test); IncobotulinumtoxinA 30 to 200 U vs Placebo; p = 0.144; LS mean difference -0.43 (95% CI -1.02 to 0.16); ANCOVA NCT02207946 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 200 iu Intramuscular

Indications